S

Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373

Watchlist Manager
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Watchlist
Price: 5.13 CNY -7.73%
Market Cap: 2.2B CNY
Have any thoughts about
Shanghai MicuRx Pharmaceutical Co Ltd?
Write Note

Shanghai MicuRx Pharmaceutical Co Ltd
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shanghai MicuRx Pharmaceutical Co Ltd
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
S
Shanghai MicuRx Pharmaceutical Co Ltd
SSE:688373
Retained Earnings
-ÂĄ1.4B
CAGR 3-Years
-40%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Retained Earnings
-ÂĄ57.7B
CAGR 3-Years
-28%
CAGR 5-Years
-44%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Retained Earnings
-ÂĄ15B
CAGR 3-Years
-12%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Retained Earnings
ÂĄ8.2B
CAGR 3-Years
70%
CAGR 5-Years
60%
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Retained Earnings
ÂĄ29.1B
CAGR 3-Years
28%
CAGR 5-Years
54%
CAGR 10-Years
47%
Imeik Technology Development Co Ltd
SZSE:300896
Retained Earnings
ÂĄ3.1B
CAGR 3-Years
56%
CAGR 5-Years
84%
CAGR 10-Years
N/A
No Stocks Found

Shanghai MicuRx Pharmaceutical Co Ltd
Glance View

Market Cap
2.2B CNY
Industry
Biotechnology

Shanghai MicuRx Pharmaceutical Co., Ltd. engages in the experimenting, discovering, and development of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 179 full-time employees. The company went IPO on 2022-08-05. The firm's antibacterial drug product, contezolid tablets, can be applied to treat infections caused by multidrug-resistant gram-positive bacteria. The firm also has a number of new anti-drug-resistant bacteria, kidney cancer, nephritis drugs and anti-new crown drug pipelines in the preclinical stage, including MRX-4, MRX-5, MRX-7, MRX-15, MRX-17 and others. The firm operates its businesses primarily in the domestic market.

Intrinsic Value
5.58 CNY
Undervaluation 8%
Intrinsic Value
Price
S

See Also

What is Shanghai MicuRx Pharmaceutical Co Ltd's Retained Earnings?
Retained Earnings
-1.4B CNY

Based on the financial report for Dec 31, 2023, Shanghai MicuRx Pharmaceutical Co Ltd's Retained Earnings amounts to -1.4B CNY.

What is Shanghai MicuRx Pharmaceutical Co Ltd's Retained Earnings growth rate?
Retained Earnings CAGR 3Y
-40%

Over the last year, the Retained Earnings growth was -45%. The average annual Retained Earnings growth rates for Shanghai MicuRx Pharmaceutical Co Ltd have been -40% over the past three years .

Back to Top